Retinal neurovascular coupling dysfunction and plasma metabolomic features as biomarkers of Alzheimer's disease: an integrated diagnostic model.

Authors

Pan Xiao, Yunxia Wang, Jian Li, Wangjun Li

Published in

Frontiers in neuroscience. Volume 20. Pages 1892148. Epub Aug 14, 2026.

Abstract

To explore features associated with impaired retinal neurovascular coupling among individuals diagnosed with Alzheimer's disease (AD) and its association with alterations in plasma metabolomics, and to establish an integrated diagnostic model for evaluating its possible significance regarding early-stage identification of AD.
We prospectively enrolled 85 AD patients, 82 subjects with mild cognitive impairment (MCI), and 83 cognitively normal controls. Retinal vessel density, foveal avascular zone (FAZ) parameters, choriocapillaris flow deficits (CCFDs), ganglion cell layer thickness, and neurovascular coupling index (NVCI) were quantified using optical coherence tomography angiography (OCTA). Untargeted plasma metabolomics was performed via ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Differential metabolites and pathways were identified, followed by correlation, regression, and receiver operating characteristic (ROC) analyses.
Compared with controls, the AD group showed reduced superficial vascular plexus perfusion density (-7.1%, P < 0.001), enlarged FAZ area (+16.1%, P < 0.001), increased CCFDs (+28.3%, P < 0.001), decreased ganglion cell layer thickness (-18.3%, P < 0.001), and lower NVCI (-12.7%, P < 0.001). Values in the MCI group were intermediate. In metabolomic profiling, AD patients had lower leucine (-17.0%, P < 0.001) and phosphatidylcholine PC(16:0/20:4) (-19.4%, P < 0.001), but higher ceramide d18:1/24:1 (+33.6%, P < 0.001) and ceramide/sphingomyelin ratio (+22.2%, P < 0.001). NVCI positively correlated with leucine (r = 0.205, q = 0.0011) and negatively with ceramide d18:1/24:1 (r = -0.139, q = 0.0280). An integrated model combining FAZ area, CCFDs, NVCI, leucine, ceramide d18:1/24:1, and PC(16:0/20:4) discriminated AD from controls with an AUC of 0.908 (95% CI: 0.865-0.952), 83.5% sensitivity, and 88.0% specificity. For predicting MCI-to-AD progression, the AUC was 0.744 (95% CI: 0.669-0.819), with 57.6% sensitivity and 85.4% specificity.
Retinal neurovascular coupling dysfunction was significantly associated with systemic metabolic disturbances (branched-chain amino acid deficiency and ceramide accumulation) in patients with AD. The OCTA-metabolomics integrated model offers excellent diagnostic performance, supporting its potential for non-invasive early AD detection and risk assessment.

PMID:
42666354
Bibliographic data and abstract were imported from PubMed on 29 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.